1. Search Result
Search Result
Results for "

EGF

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

9

Peptides

1

MCE Kits

4

Inhibitory Antibodies

6

Natural
Products

52

Recombinant Proteins

2

Isotope-Labeled Compounds

13

Antibodies

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12872B

    EGF816 (S-enantiomer)

    EGFR Others
    Nazartinib S-enantiomer (EGF816 S-enantiomer) is the less active S-enantiomer of Nazartinib. Nazartinib (EGF816) is an EGFR inhibitor.
    Nazartinib S-enantiomer
  • HY-12872
    Nazartinib
    5+ Cited Publications

    EGF816

    EGFR Cancer
    Nazartinib (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min −1 on EGFR(L858R/790M) mutant, respectively.
    Nazartinib
  • HY-P0320

    Phosphatase Others
    EGF Receptor Substrate 2 (Phospho-Tyr5) acetate, a biologically active peptide, is a tyrosine phosphate substrate. EGF Receptor Substrate 2 (Phospho-Tyr5) acetate can be used to detect protein tyrosine phosphatases activity .
    EGF Receptor Substrate 2 (Phospho-Tyr5)
  • HY-RS16498

    Small Interfering RNA (siRNA) Others

    Egf Mouse Pre-designed siRNA Set A contains three designed siRNAs for Egf gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Egf Mouse Pre-designed siRNA Set A
    Egf Mouse Pre-designed siRNA Set A
  • HY-RS04204

    Small Interfering RNA (siRNA) Others

    EGF Human Pre-designed siRNA Set A contains three designed siRNAs for EGF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    EGF Human Pre-designed siRNA Set A
    EGF Human Pre-designed siRNA Set A
  • HY-RS22928

    Small Interfering RNA (siRNA) Others

    Egf Rat Pre-designed siRNA Set A contains three designed siRNAs for Egf gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Egf Rat Pre-designed siRNA Set A
    Egf Rat Pre-designed siRNA Set A
  • HY-12872A

    EGF816 mesylate

    EGFR Cancer
    Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min −1 on EGFR(L858R/790M) mutant, respectively.
    Nazartinib mesylate
  • HY-P0320B

    Phosphatase Biochemical Assay Reagents Others
    EGF Receptor Substrate 2 (Phospho-Tyr5) acetate, a biologically active peptide, is a tyrosine phosphate substrate. EGF Receptor Substrate 2 (Phospho-Tyr5) acetate can be used to detect protein tyrosine phosphatases activity .
    EGF Receptor Substrate 2 (Phospho-Tyr5) (acetate)
  • HY-P0320A

    Phosphatase Biochemical Assay Reagents Others
    EGF Receptor Substrate 2 (Phospho-Tyr5) acetate, a biologically active peptide, is a tyrosine phosphate substrate. EGF Receptor Substrate 2 (Phospho-Tyr5) acetate can be used to detect protein tyrosine phosphatases activity .
    EGF Receptor Substrate 2 (Phospho-Tyr5) (TFA)
  • HY-P3918

    p38 MAPK Others
    EGF-R (661-681) T669 Peptide is a MAPK substrate that can used to measure MAPK catalytic activity .
    EGF-R (661-681) T669 Peptide
  • HY-103440

    EGFR Cancer
    EGFR/ErbB-2/ErbB-4 inhibitor-3 (compound 29) is a potent tyrosine kinase inhibitor with IC50s of 0.3, 1.1, 0.5, 2.5, 24 nM for erbB1, erbB2, erbB4, EGF, HER, respectively . EGFR/ErbB-2/ErbB-4 inhibitor-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    EGFR/ErbB-2/ErbB-4 inhibitor-3
  • HY-P99041
    Panitumumab
    1 Publications Verification

    ABX-EGF

    EGFR Cancer
    Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
    Panitumumab
  • HY-P99041B

    ABX-EGF (powder)

    EGFR Cancer
    Panitumumab (ABX-EGF) (powder) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (powder) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (powder) can be used in the research of cancers, such as colon cancer .
    Panitumumab (powder)
  • HY-117523

    (Z)-Tyrphostin RG13022

    EGFR Cancer
    (Z)-RG-13022 is a tyrosine kinase (TK) inhibitor, which inhibits preferentially the TK activity of the EGF receptor and inhibits EGF-stimulated growth of cultured cells. (Z)-RG-13022 exerts an IC50 of 11 μM for DNA synthesis in the HN5 cells, which is 3 times more potent than (E)-RG-13022 (IC50=38 μM). (Z)-RG-13022 can be used for research of breast cancer cells .
    (Z)-RG-13022
  • HY-P2673

    KRTLRR

    EGFR Others
    Lys-Arg-Thr-Leu-Arg-Arg (KRTLRR) is a hexapeptide. Lys-Arg-Thr-Leu-Arg-Arg is a substrate of protein kinase C from EGF receptor. Lys-Arg-Thr-Leu-Arg-Arg can be used to determine the activity of protein kinase C .
    Lys-Arg-Thr-Leu-Arg-Arg
  • HY-114667

    EGFR Others
    Lavendustin C6 is a specific inhibitor of tyrosine kinase. Lavendustin C6 inhibits epidermal growth factor (EGF) receptor tyrosine kinase with an EC50 value of 0.05 μg/mL. Lavendustin C6 inhibits platelet-derived growth factor (PDGF)-induced inositol phosphate formation .
    Lavendustin C6
  • HY-104064
    1A-116
    5+ Cited Publications

    Ras Apoptosis Cancer
    1A-116, a potent Rac1 inhibitor, is specific for W56 residues, can prevent EGF-induced Rac1 activation and block Rac1-P-Rex1 interaction. 1A-116 can induce apoptosis and inhibit cell proliferation, migration and cycle progression in a concentration-dependent manner. 1A-116 also demonstrates a high antimetastatic activity in vivo .
    1A-116
  • HY-149352

    Thymidylate Synthase Cancer
    DG1 (Compound 8Nc) is a Thymidylate Synthase (TS) inhibitor that affects cancer angiogenesis and metabolic reprogramming in NSCLC cells. DG1 can effectively inhibit the expression of CD26, ET-1, FGF-1 and EGF. DG1 also effectively inhibits the proliferation of cancer tissue in the A549 xenograft mouse model .
    DG1
  • HY-124152

    Methyl-3,4-dephostatin

    MAP3K MAP4K Phosphatase Neurological Disease
    3,4-Dephostatin (Methyl-3,4-dephostatin) is an inhibitor of protein-tyrosine phosphatase (PTPase). 3,4-Dephostatin accelerates nerve growth factor (NGF)-induced neurite formation in PC12h cells. 3,4-Dephostatin sustains the NGF-induced tyrosine phosphorylation of proteins, most prominently that of mitogen-activated protein (MAP) kinase. 3,4-Dephostatin also prolongs epidermal growth factor (EGF)-induced tyrosine phosphorylation and activation of MAP kinase .
    3,4-Dephostatin
  • HY-N14173

    Antibiotic Fungal Infection
    Epiderstatin is a glutarimide antibiotic. Epiderstatin has the activity of inhibiting the filamentous division induced by epidermal growth factor (EGF), but does not inhibit EGF-receptor kinase. Epiderstatin has only weak antifungal activity and no antibacterial effect .
    Epiderstatin
  • HY-108931

    EGFR Cancer
    AG 1406 (compound M19) is a HER2 inhibitor, with an IC50 of 10.57 μM for HER2 in BT474 cell and >50 μM for EGFR in EGF-3T3 cell .
    AG 1406
  • HY-101756

    SDZ-LAP 977

    EGFR Cancer
    SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.
    SDZ281-977
  • HY-101429
    RG13022
    1 Publications Verification

    Tyrphostin RG13022

    EGFR Cancer
    RG13022 is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC50 of 4 μM.
    RG13022
  • HY-50895A
    Gefitinib hydrochloride
    Maximum Cited Publications
    144 Publications Verification

    ZD-1839 hydrochloride

    EGFR Cancer
    Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib hydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib hydrochloride also induces autophagy. Gefitinib hydrochloride has antitumour activity .
    Gefitinib hydrochloride
  • HY-N14910

    Antibiotic Bacterial Infection
    Actiketal is a glutarimide antibiotic that inhibits the incorporation of [ 3H]thymidine into EGF-stimulated Balb/MK cells .
    Actiketal
  • HY-131257

    Drug Metabolite Others Cancer
    Gefitinib impurity 1 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity .
    Gefitinib impurity 1
  • HY-133779

    Drug Metabolite Others Cancer
    Gefitinib impurity 5 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity .
    Gefitinib impurity 5
  • HY-50895S1

    ZD1839-d6

    EGFR Autophagy Cancer
    Gefitinib-d6 is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity .
    Gefitinib-d6
  • HY-P99155

    EGFR Cancer
    Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
    Zalutumumab
  • HY-50895B

    ZD 1839 dihydrochloride

    EGFR Autophagy Apoptosis Cancer
    Gefitinib (ZD 1839) dihydrochloride is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib dihydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib dihydrochloride also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
    Gefitinib dihydrochloride
  • HY-100663

    EGFR Others Cancer
    Gefitinib impurity 2 is the impurity of Gefitinib. Gefitinib (ZD1839; HY-50895) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity .
    Gefitinib impurity 2
  • HY-50895
    Gefitinib
    Maximum Cited Publications
    144 Publications Verification

    ZD1839

    EGFR Autophagy Apoptosis Cancer
    Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
    Gefitinib
  • HY-P99155A

    EGFR Cancer
    Zalutumumab (powder) is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab (powder) binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab (powder) binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab (powder) can be used for the research of cancer .
    Zalutumumab (powder)
  • HY-147279

    LDLR Others
    Milpocitide is a low-density lipoprotein receptor (human LDL receptor, LDLR), (293-333)-peptide fragment (EGF-like domain 1) .
    Milpocitide
  • HY-116111

    PDGFR Cardiovascular Disease
    AG 370, an indole tyrphostin, is a potent PDGF-induced mitogenesis inhibotor (IC50 of 20 μM). AG 370 displays weak inhibition of the EGF receptor .
    AG 370
  • HY-50895S2

    Isotope-Labeled Compounds EGFR Autophagy Cancer
    Gefitinib-d3 (ZD1839-d3) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity .
    Gefitinib-d3
  • HY-50895R

    ZD1839 (Standard)

    EGFR Autophagy Apoptosis Cancer
    Gefitinib (Standard) is the analytical standard of Gefitinib. This product is intended for research and analytical applications. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
    Gefitinib (Standard)
  • HY-133779R

    Drug Metabolite Others Cancer
    Gefitinib impurity 5 (Standard) is the analytical standard of Gefitinib impurity 5. This product is intended for research and analytical applications. Gefitinib impurity 5 is the impurity of Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy. Gefitinib has antitumour activity .
    Gefitinib impurity 5 (Standard)
  • HY-13595
    Chrysophanol
    3 Publications Verification

    Chrysophanic acid

    EGFR Cancer
    Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K.
    Chrysophanol
  • HY-NP185

    Biochemical Assay Reagents Others
    Chicken Tenascin,suitable for cell culture 是一种糖蛋白,可形成二硫键连接的六聚体。Chicken Tenascin,suitable for cell culture 由重复的结构域组成,包括 EGF 样重复序列、纤连蛋白 III 型重复序列和与纤维蛋白原同源的区域。Chicken Tenascin,suitable for cell culture 可用于细胞培养。
    Chicken Tenascin,suitable for cell culture
  • HY-NP184

    Biochemical Assay Reagents Others
    Human Tenascin,suitable for cell culture 是一种糖蛋白,可形成二硫键连接的六聚体。Human Tenascin,suitable for cell culture 由重复的结构域组成,包括 EGF 样重复序列、纤连蛋白 III 型重复序列和与纤维蛋白原同源的区域。Human Tenascin,suitable for cell culture 可用于细胞培养。
    Human Tenascin,suitable for cell culture
  • HY-101957
    AG 1295
    4 Publications Verification

    PDGFR Cardiovascular Disease
    AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .
    AG 1295
  • HY-P2673A

    KRTLRR acetate

    Fluorescent Dye EGFR Cancer
    Lys-Arg-Thr-Leu-Arg-Arg (KRTLRR) acetate is a hexapeptide. Lys-Arg-Thr-Leu-Arg-Arg acetate is a substrate of EGF receptor protein kinase C and can be used to measure protein kinase C activity .
    Lys-Arg-Thr-Leu-Arg-Arg acetate
  • HY-118175

    EGFR Others
    RG 14921 is a compound structurally related to Erbstatin (HY-113549) and has inhibitory activity against EGFR tyrosine kinase and CAMP-dependent kinase activity. RG 14921 inhibits EGF receptor kinase activity as a noncompetitive inhibitor.
    RG 14921
  • HY-145967
    FT709
    1 Publications Verification

    Deubiquitinase Mitosis Cancer
    FT709 is a potent and selective USP9X inhibitor, an IC50 of 82 nM. USP9X has been linked with centrosome function, chromosome alignment during mitosis, EGF receptor degradation, chemo-sensitization, and circadian rhythms .
    FT709
  • HY-N6674

    ECO-4601; TLN-4601; BU 4664L

    Ras Apoptosis Cancer
    Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models .
    Diazepinomicin
  • HY-13896
    PD168393
    3 Publications Verification

    EGFR Autophagy Apoptosis Cancer
    PD168393 is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC50=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .
    PD168393
  • HY-N5190

    Antibiotic Bacterial Infection
    Enamidonin is a lipopeptide antibiotic. Enamidonin inhibits EGF-dependent [ 3H] thymidine involvement in Balb/MK cells (IC50 is 10 μg/mL), and it can restore the deformed SRCTS-NRK form to the normal flat form (ED50 is 10 μg/mL). No antimicrobial activity .
    Enamidonin
  • HY-171443

    Lyso-GM3

    EGFR Drug Derivative Cancer
    Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analogue of Ganglioside GM3 (HY-114456) with antitumor activities. Lyso-Monosialoganglioside inhibits EGF-induced increases in EGFR kinase activity in A431 epithelial cancer cells .
    Lyso-Monosialoganglioside GM3
  • HY-P10697

    LDLR Metabolic Disease
    VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
    VH4127

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: